Please login to the form below

Not currently logged in
Email:
Password:

Alliance Pharma to buy Cambridge Labs

Alliance Pharma has signed a conditional agreement to buy Cambridge Laboratories' UK and Ireland-based businesses

Alliance Pharma has signed a conditional agreement to buy Cambridge Laboratories' UK and Ireland-based businesses for a base price of £14.3m in cash and shares.

The deal also includes the value of its inventory at the time of completion, expected on 22 February 2010, and an additional deferred contingent payment of £1.6m-£2.1m.

The acquisition includes 18 prescription products across a range of therapeutic areas including ImmuCyst, an immunotherapy for superficial bladder cancer; Gelclair, an oral gel for managing oral mucositis in chemotherapy patients; and procarbazine, a treatment for Hodgkin's Lymphoma.

Combined sales of ImmuCyst, Gelclair, and procarbazine represent 40 per cent of Cambridge Laboratories total sales in 2009. Sales for the three products have also been growing at a combined rate of about 18 per cent per annum over the last three years.

The £1.6m-£2.1m deferred contingent consideration will be payable if ImmuCyst's licence is extended beyond March 2012. The final amount will depend on its sales figures during 2010 and 2011.

9th February 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...